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Background: The skin is a key route of human exposure to nanomaterials, which typically occurs simultaneously
with exposure to other chemical and environmental allergen. However, little is known about the hazards of
nanomaterial exposure via the skin, particularly when accompanied by exposure to other substances.
Results: Repeated topical treatment of both ears and the shaved upper back of NC/Nga mice, which are models
for human atopic dermatitis (AD), with a mixture of mite extract and silica nanoparticles induced AD-like skin
lesions. Measurements of ear thickness and histologic analyses revealed that cutaneous exposure to silica nanoparticles
did not aggravate AD-like skin lesions. Instead, concurrent cutaneous exposure to mite allergens and silica nanoparticles
resulted in the low-level production of allergen-specific IgGs, including both the Th2-related IgG1 and Th1-related
IgG2a subtypes, with few changes in allergen-specific IgE concentrations and in Th1 and Th2 immune responses. In
addition, these changes in immune responses increased the sensitivity to anaphylaxis. Low-level IgG production was
induced when the mice were exposed to allergen–silica nanoparticle agglomerates but not when the mice exposed to
nanoparticles applied separately from the allergen or to well-dispersed nanoparticles.
Conclusions: Our data suggest that silica nanoparticles themselves do not directly affect the allergen-specific immune
response after concurrent topical application of nanoparticles and allergen. However, when present in allergen-
adsorbed agglomerates, silica nanoparticles led to a low IgG/IgE ratio, a key risk factor of human atopic allergies.
We suggest that minimizing interactions between nanomaterials and allergens will increase the safety of nanomaterials
applied to skin.
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Because of their unique features and physicochemical
properties [1, 2], nanomaterials are increasingly being
used to add value to new and existing goods, such as
cosmetics, foods, medicines, and industrial products [3–5].
However, these same novel features of nanomaterials make
them hazardous under some conditions [6, 7]. To take full
advantage of the potential benefits of nanomaterials, we
must learn more about their hazards so that safer nanoma-
terials can be designed.
Numerous epidemiologic studies have prompted con-
cerns regarding the health risks associated with exposure
to nanomaterials; in particular, such studies have re-
vealed that exposure to particulate matter (PM), includ-
ing PM2.5 and Asian dust, induces many adverse effects,
including facilitating the onset and severity of allergic
diseases [8–11]. Because inhalational exposure to PM
has been considered to be the main inducer of these ad-
verse effects, this route has received the most attention
regarding exposure to nanomaterials [12]. However, the
skin is a major route of both intentional (from clothing,
cosmetics, and other skin care products) and uninten-
tional (from the environment) exposure to nanomater-
ials [13–15]. Furthermore, exposure to nanomaterials
often occurs simultaneously with exposure to other
chemical compounds and environmental allergens [16],
but little is known about the hazards of cutaneous expos-
ure to nanomaterials, particularly in combination with
other substances.
In the current study, we investigated the effects of con-
current topical application of mite extract and amorphous
silica nanoparticles, one of the most widely used nanoma-
terials, on allergic sensitization and AD in NC/Nga mice,
a murine model of AD. We found that cutaneous expos-
ure to the allergen and silica nanoparticles simultaneously
did not aggravate AD-like skin lesions in the mice but re-
sulted in low-level IgG production with little change in
IgE production (IgE-biased immune response) and in-
creased sensitivity to anaphylaxis. We suggest that an IgE-
biased immune response was induced independently of
the innate biologic effects of silica nanoparticles. Because
a low IgG/IgE ratio is a characteristic feature of human
atopic allergy, we believe that minimizing interactions be-
tween nanomaterials and allergens may improve the safety
of cutaneously applied nanomaterials.
Results and discussion
Effects of co-exposure to mite allergen and silica nano-
particles in a murine model of AD
For these experiments, we used silica nanoparticles with
a diameter of 30 nm (nSP30). Solutions of nSP30 were
clear and colorless (Fig. 1a), and transmission electron mi-
croscopy (TEM) revealed that the particles were smooth
spheres (Fig. 1b). The size distribution spectrum of nSP30was a single peak (Fig. 1c), and the mean hydrodynamic
diameter (24.1 nm, as measured by means of a dynamic
light-scattering method; Fig. 1d) corresponded almost
exactly to the primary particle size. These results indicate
that the nSP30 particles were well dispersed in solution.
To examine the effects of co-exposure of skin to aller-
gen and nSP30, we used an extract of the mite Dermato-
phagoides pteronyssinus (Dp) and NC/Nga mice as a
model for human AD [17]. Dp is a frequent cause of many
allergic conditions, including asthma and AD [18, 19]. In
addition, NC/Nga mice have a genetic skin barrier defect
related to low ceramide production [20]. To induce AD-
like skin lesions, we repeatedly cutaneously exposed NC/
Nga mice to either Dp alone or a mixture of Dp and
nSP30 in an isotonic solution (phosphate buffered saline;
PBS). Note that although the solutions of Dp alone and
nSP30 alone were clear and colorless, the mixture of
Dp + nSP30 was cloudy (Fig. 1a). TEM images suggested
that mixing resulted in the formation of agglomerates
(Fig. 1b), which was confirmed by the fact that the mean
hydrodynamic diameter of the particles in the mixture
was 1310.0 nm, which was larger than that of nSP30 alone
(Fig. 1c and d). First, we confirmed that exposure to
nSP30 alone did not induce the formation of topical skin
lesions (Additional file 1). Comparison of the PBS and
Dp-alone groups indicated that cutaneous exposure to Dp
induced ear thickening, scab formation, acanthosis, in-
flammatory cell infiltration, and mast cell infiltration
(Fig. 2a–e). The effects of cutaneous exposure to Dp +
nSP30 did not differ from those of Dp alone, except
that the extent of ear thickening was slightly less in the
Dp + nSP30 group than in the Dp-alone group.
Total IgE levels in plasma, which are often elevated in
AD and other allergic conditions [21], were measured
24 h after the final treatment. The total IgE level in the
Dp-alone group was higher than that in the PBS group
(Fig. 2f ), and the total IgE level in the Dp + nSP30 group
was slightly higher than that in the Dp-alone group
(Fig. 2f ). Because a Th2-mediated immune response in-
cluding IgE production is unnecessary for the develop-
ment of AD-like skin lesions in NC/Nga mice [22], the
high total IgE level induced by cutaneous exposure to
Dp + nSP30 likely did not exacerbate the Dp-induced
AD-like skin lesions in NC/Nga mice.
Effect of cutaneous exposure to Dp + nSP30 on cutaneous
allergic sensitization
To clarify the effect of topical Dp + nSP30 on cutaneous
allergic sensitization, we evaluated the systemic immune
responses 24 h after the final treatment. Although Dp-
specific IgE levels were higher in both the Dp-alone
group and the Dp + nSP30 group than in the PBS group,
Dp-specific IgE levels did not differ significantly between















Sample Vehicle Diameter (nm)a Zetapotential (mV)b
nSP30 PBS 24.1 0.3 –24.6 2.1
nSP30C PBS 20.5 0.5 –32.3 0.9
Dp + nSP30 PBS 1310.0 98.5a –20.2 1.1
Dp + nSP30C PBS 24.8 1.1 –28.9 0.0
nSP30 water 19.5 1.6 Not applicable
Dp + nSP30 water 20.0 0.6 Not applicable
Data are expressed as means SDs (n = 3).
a Peak size of histograms.
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Fig. 1 Physicochemical properties of silica nanoparticles alone and combined with allergen. a Macroscopic and (b) transmission electomicrographic
images of the samples used in this study (scale bar, 100 nm). c Particle size distributions of samples diluted in PBS or water measured by using a
dynamic light scattering method. d Mean particle diameters and zeta potentials of samples
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Fig. 2 Induction of AD-like skin lesions by Dp + nSP30 agglomerates in PBS. a Effect of topical administration of Dp alone or Dp + nSP30 in PBS
on ear thickness in NC/Nga mice. b and c, Histology of ear sections stained with (b) hematoxylin and eosin (HE) or (c) toluidine blue (TB). Scale
bar, 50 μm. (d) Scores for several symptoms characteristic of AD evaluated in HE-stained sections. e Mast cell infiltration evaluated in TB-stained
sections as the number of mast cells per high-power (400×) field (HPF). f Total plasma IgE concentrations measured 24 h after the final skin painting.
Data are presented as means ± SEMs (n = 5). *P < 0.05 vs. Dp-alone group
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evaluated IgG subtypes were significantly lower in the
Dp + nSP30 group than in the Dp-alone group (Fig. 3b
and c). In addition, we confirmed that nSP30 dose-
dependently suppressed IgG production (Additional file
2). IgG subclass responses have been used to assess the
type of immune response; IgG1 is known to indicate a
Th2-type response, whereas IgG2a indicates a Th1 re-
sponse [23]. Thus it is possible that skin exposure toDp + nSP30 suppressed both the Th1 and the Th2
responses.
To further characterize the systemic immune responses,
we enumerated the Dp-specific splenocytes secreting
interferon-γ (IFN-γ) and interleukin-4 (IL-4) in each
mouse by using cytokine-specific enzyme-linked immuno-
sorbent spot (ELISPOT) assays (Fig. 3d). The numbers of
Dp-specific IFN-γ- and IL-4-secreting splenocytes did not
differ between the Dp-alone group and the Dp + nSP30
Fig. 3 Induction of systemic immune responses by Dp + nSP30 agglomerates in PBS. a–c Plasma levels of Dp-specific (a) IgE, (b) IgG, and (c) IgG1
and IgG2a as analyzed by ELISA at 24 h after final topical treatment of NC/Nga mice with Dp alone or Dp + nSP30 in PBS. (D) Numbers of Dp-specific
IFN-γ- and IL-4-producing splenocytes after re-stimulation with 100 μg mL−1 Dp, as determined by using ELISPOT assays specific for each cytokine. Data
are given as means ± SEMs (n = 5–12). **P < 0.01 vs. Dp-alone group
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supernatants of splenocytes was significantly lower in the
Dp + nSP30 group than in the Dp-alone group, none of
the other measured cytokines (IL-5, 10, 13, and 17) dif-
fered between these groups (Additional file 3). Therefore,
nSP30 might have affected IgG production without alter-
ing systemic Th1 and Th2 immune responses. Because IL-
21 is a critical factor in IgG production [24, 25], additional
study of IL-21 likely would help to clarify the mechanism
underlying the reductions in both the IgG1 and IgG2a
subtypes.Recently, the skin was revealed to be the key initial site
of allergic sensitization not only for allergic eczema but
also for other atopic allergies, including allergic rhinitis,
asthma, and food allergies [26–28]. Therefore, skin might
play a special role in allergic sensitization. To this end, we
assessed the effects of exposure to Dp + nSP30 by various
other exposure routes on the IgG response (Additional file
4). Consistent with our previously reported results [29],
nSP30-mediated IgG suppression was not observed
after intranasal, oral, or intradermal administration of
Dp + nSP30, thus suggesting that the low IgG response
Fig. 4 Sensitivity to anaphylactic shock. Time-dependence of change
in rectal temperature in NC/Nga mice due to intravenous challenge
with Dp after treatment with Dp alone or Dp + nSP30 in PBS. Data
are given as means ± SEMs (n = 6). *P < 0.05 vs. Dp-alone group
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Dp + nSP30.
Effect of cutaneous exposure to Dp + nSP30 on
susceptibility to anaphylaxis
Chemical mediators such as histamine and various cyto-
kines induce the typical symptoms of atopic allergy,
including inflammation and itching [30, 31]. The pro-
duction of these chemical mediators is induced when
an allergen cross-links IgE molecules bound to high-
affinity IgE receptors (FcεRI) on mast cells and baso-
phils. However, allergen-specific IgG, considered to be
the ‘blocking antibody’, may neutralize allergen molecules
before they can interact with IgE [32, 33]. Furthermore,
IgG–allergen complexes act through a pathway regulated
by the inhibitory receptor FcγRIIB to inhibit IgE-mediated
mast cell and basophil signaling [32–34]. Therefore, the
presence of allergen-specific IgG inhibits IgE-mediated al-
lergic responses. Because our results showed that Dp +
nSP30 led to low levels of Dp-specific IgG with little
change in the levels of Dp-specific IgE (Fig. 3a–c), we
examined whether this IgE-biased immune response in-
duced by cutaneous exposure to Dp + nSP30 caused
IgE-mediated hypersensitivity to Dp in a systemic ana-
phylaxis model. The decrease in rectal temperature
after challenge with intravenous Dp was significantly
greater in mice sensitized by Dp + nSP30 than in those
sensitized by Dp alone (Fig. 4). That is, mice in the Dp +
nSP30 group were more sensitive to the induction of Dp-
specific anaphylaxis than were those in the Dp-alone
group. Together, concurrent cutaneous exposure to Dp
and nSP30 induced IgE-biased immune responses and,
subsequently, increased sensitivity to anaphylaxis. In con-
trast, the functions of specific immunoglobulin subtypes
vary between mice and humans; for example, blocking
antibodies in humans are considered to be of the IgG4
subtype, which mice lack [35]. Therefore, our results can-
not be extrapolated directly to humans. In addition, regu-
latory T and B cells have recently been suggested to be the
main suppressors of atopic allergy in allergen-specific im-
munotherapy [36]. Additional study is needed to clarify
whether increases in anaphylactic sensitivity is solely due
to blocking antibody.
Effects of sequential cutaneous exposure to allergen and
nSP30 on the IgE-biased immune response
We also evaluated the effects of sequential (rather than
concurrent) cutaneous exposure to Dp and nSP30; that
is, we topically applied Dp and nSP30 on alternate days
rather than applying them together on the same day. Ear
thickening and changes in total IgE concentration result-
ing from alternate-day application of Dp and nSP30
(Dp/nSP30) did not differ significantly from those result-
ing from concurrent treatment with Dp and PBS everyother day (Dp/PBS) (Fig. 5a and b). Taken together, our
results indicate that cutaneous exposure to nSP30 did
not aggravate Dp-induced AD-like skin lesions regard-
less of whether the nanoparticles were applied together
with or separately from Dp. In addition, alternate-day
skin painting with Dp and nSP30 induced Dp-specific
IgE and IgG production and Dp-specific IFN-γ- and IL-
4-secreting splenocytes in the same way as did topical
application of Dp and PBS (Fig. 5c–f ). Therefore, expos-
ure to both Dp and nSP30 was necessary to induce an
IgE-biased immune response. Given that Dp + nSP30
formed agglomerates (Fig. 1), an interaction between Dp
and nSP30 may have contributed to the subsequent IgE-
biased immune response.
Effects of agglomeration of allergen and nSP30 on the
IgE-biased immune response
Because the surface properties of nanomaterials strongly
influence their interactions with proteins [37], we inves-
tigated how surface modification of nSP30 with carboxyl
groups affected the interaction between Dp and nSP30
and the subsequent IgE-biased immune response. Solu-
tions of the mixture of Dp and nSP30 modified with sur-
face carboxyl groups (nSP30C) were clear and colorless
(Fig. 1a), and a TEM image of Dp + nSP30C was similar
to that of nSP30C alone (Fig. 1b). The mean hydro-
dynamic diameter of Dp + nSP30C was 24.8 nm, which
Fig. 5 (See legend on next page.)
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Fig. 5 Effects of Dp + nSP30 aggregates compared with Dp and nSP30 administered on alternate days. a Effect of topical application of Dp + nSP30
and PBS (Dp + nSP30/PBS) compared with Dp and nSP30 (Dp/nSP30) on alternate days on ear thickness in NC/Nga mice. b–e Plasma levels of (b) total
IgE, (c) Dp-specific IgE, (d) IgG and (e) IgG1 and IgG2a 24 h after final treatment, as analyzed by ELISA. f Numbers of Dp-specific IFN-γ- and IL-4-
producing splenocytes after re-stimulation with 100 μg mL−1 Dp, as determined by ELISPOT assays specific for each cytokine. Data are presented as
means ± SEMs (n = 5). *P < 0.05, **P < 0.01 vs. Dp/PBS group
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alone (Fig. 1c and d). These results suggest that the mixing
of Dp and nSP30C did not result in substantial agglomer-
ation. The level of Dp-specific IgE induced by cutaneous
exposure to Dp + nSP30C was the same as that induced
by cutaneous exposure to Dp alone or to Dp + nSP30
(Fig. 6a). Although cutaneous exposure to Dp + nSP30 sig-
nificantly reduced the levels of Dp-specific IgG and its
subtypes, cutaneous exposure to Dp + nSP30C had little
effect on the levels of Dp-induced IgG, IgG1, and IgG2a
(Fig. 6b and c).
The vehicle in which nanoparticles are suspended is a
key determinant of their dispersion and affects their toxicity
[38, 39]. To further evaluate the effect of agglomeration of




























Fig. 6 Prevention of Dp + nSP30-mediated IgE-biased immune response by
IgE, (b) IgG, and (c) IgG1 and IgG2a at 24 h after final treatment of NC/Nga
ELISA. Data are given as means ± SEMs (n = 5). *P < 0.05, **P < 0.01 vs. Dp-atested the effect of the vehicle on the formation of agglom-
erates and the IgE-biased immune response. Solutions of
Dp and nSP30, either individually or together, in water were
clear and colorless, but the combination of Dp and nSP30
in PBS was cloudy (Fig. 1a). The mean hydrodynamic
diameter of nSP30 in water was 19.5 nm and that of Dp +
nSP30 in water was 20.0 nm (Fig. 1c and d), indicating that
mixing Dp and nSP30 in water did not cause agglomer-
ation. We repeatedly painted NC/Nga mice with Dp +
nSP30 in water and evaluated the Dp-induced antibody re-
sponses. When suspended in water, nSP30 had no effect on
the level of Dp-specific IgE (Fig. 7a). In addition, the levels
of Dp-specific total IgG, IgG1, and IgG2a did not differ
between the Dp + nSP30 and Dp-alone groups when












































surface modification of nSP30. a–c Plasma levels of Dp-specific (a)




















































































Fig. 7 Effect of topical application of dispersed mixture of Dp + nSP30 on antibody response. a–c Plasma levels of Dp-specific (a) IgE, (b) IgG, and
(c) IgG1 and IgG2a at 24 h after final topical treatment of NC/Nga mice with Dp alone or Dp + nSP30 in water, as analyzed by ELISA. Data are
given as means ± SEMs (n = 5 or 6). *P < 0.05, **P < 0.01 vs. Dp-alone group
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to impede the allergen-specific IgG response, but it did
not affect the IgE response.
Atopic patients typically have relatively low IgG/IgE
ratios [40, 41]. In addition, human studies indicate that
IgE production in the absence of IgG production is a key
risk factor for the onset of atopic allergy [42]. Low-dose
exposure to allergen sometimes induces a low IgG/IgE
ratio in both mice and humans [43, 44]. Therefore, the
formation of agglomerates in our experimental system
may, in effect, decrease allergen doses and then induce
an IgE-biased immune response. To assess the amount
of unbound Dp, we compared the Dp concentration in
the supernatant after centrifugation. After centrifugation,
the Dp concentration in the supernatant of the Dp-alone
group was somewhat lower than that observed before
centrifugation (1000 μg/mL→ 457 μg/mL) (Fig. 8). Mix-
ing Dp and nSP30 together in PBS decreased the Dp
concentrations in the supernatants in an nSP30-
dependent manner (Fig. 8). In contrast, mixing Dp with
nSP30C in PBS or with nSP30 in water had little effect
on the Dp concentration in the supernatant comparedwith that of the Dp-alone group. Therefore, agglomer-
ation might increase the amount of Dp absorbed to
nSP30. Considering the fact that, in general, aggregates
and agglomerates of nanomaterials have difficulty pene-
trating the skin barrier [45], the agglomeration of Dp
and nSP30 might decrease the exposure dose of Dp
somewhat even when the agglomerates release Dp on
the skin.
We previously examined the Dp dose-effect in the
same NC/Nga model (Hirai T. et al., submitted paper).
In that study, levels of both Dp-specific IgE and IgG
were correlated with exposure amount of Dp in the
range of 30 to 120 μg Dp mouse−1; in the current study,
we used a dose of 120 μg Dp mouse−1 for the Dp-alone
group. Furthermore, the Th2-related cytokine response
in Dp-stimulated splenocytes was lower in the120-μg Dp
mouse−1 group than in other (lower) dose groups. In
contrast, we show here that the exposure to agglomerates
of Dp and nSP30 in PBS induced a dampened Dp-specific
IgG response with little change in the Dp-specific IgE and
Th1/Th2 immune responses compared with those of the
Dp-alone group (Fig. 3 and Additional file 3). Together,
Fig. 8 Evaluation of absorption of Dp to nSP30. The amount of Dp in the supernatant of each centrifuged sample was determined (OD280). Data
are given as means ± SD (n = 3). **P < 0.01 vs. Dp-alone
Hirai et al. Particle and Fibre Toxicology  (2015) 12:16 Page 10 of 14these observations suggest that the IgE-biased immune re-
sponse in the current study was not solely due to the low
Dp exposure resulting from the agglomeration of Dp and
nSP30. Perhaps the agglomerates of Dp and nSP30 in PBS
not only decreased the Dp exposure dose but also behaved
as a ‘depot,’ thus controlling the allergen concentration,
prolonging allergen exposure, and subsequently causing
IgE-biased allergic sensitization. We believe additional
studies that focus on the effect of nanoparticles on aller-
gen penetration kinetics in the skin would be beneficial to
confirm the safety of cutaneous exposure to nanomater-
ials. However, we acknowledge the need for additional
studies in which the exposure scenario is more representa-
tive of that in humans to define the safety of concurrent
cutaneous exposure to nanomaterials and allergen.
It is well recognized that there are some situations in
our daily lives, the development of atopic allergy is
inhibited by higher dose exposure to allergen due to
high induction of blocking IgG [46–48]. Particularly in
these high-dose exposure situations, we suggest that
allergen-nanoparticle agglomerates, by inducing IgE-
biased immune responses, might play a critical role in
the development of atopic allergy. In addition, the IgE-
biased immune response induced by cutaneous exposure
to agglomerates of allergen and nanoparticles in our
mice was similar to those humans with atopic allergies,
who often have a low IgG/IgE ratio, as mentioned earlier
[40, 41]. Therefore epidemiologic studies that address
cutaneous as well as inhalational exposure to nanoma-
terials may improve our understanding of the onset of
atopic allergy.
Recently, Ilves M. et al. described the effects of cutaneous
exposure to nano-sized ZnO (nZnO) administered withmodel antigens, ovalbumin and staphylococcal enterotoxin
B, on AD-like skin lesions and antibody responses [49].
Interestingly, the effects observed for nZnO and an antigen
were similar to the effects of agglomerates of Dp and
nSP30: nZnO suppressed allergen-induced skin inflamma-
tion and induced low-level IgG production in the context
of a high IgE response. The authors of the previous study
[49] did not address changes of nZnO dispersibility by mix-
ing allergen, but considering that nZnO is predisposed to
forming agglomerates and might adsorb a coexisting sub-
stance [50], nZnO might play similar role to that of nSP30.
To better understand the hazards of nanomaterials so that
we can maximize their potential benefits, we should pay in-
creased attention to the state of nanoparticles (e.g. dispersi-
bility) in administration in nanotoxicology studies. We
consider this focus particularly applicable in the hazard
evaluation of nanomaterials that are in the presence of
other substances, which could interact with them.
Cutaneous exposure to aggregates or agglomerates of
nanomaterials is generally considered to be safer than is
similar exposure to individual nanoparticles, mainly be-
cause agglomerates of nanomaterials have difficulty
penetrating the skin [50]. However, Dp and nSP30 in-
duced an IgE-biased immune response only when they
formed agglomerates. Although these results represent
only indirect effects of nanomaterials, we think that haz-
ard identification is necessary even when nanomaterials
are considered to be unable to cross the skin barrier (e.g.
when nanomaterials form aggregates or agglomerates).
In contrast, surface modification of the nSP30 with carb-
oxyl groups suppressed the adsorption of the allergen and
did not induce IgE-biased allergic sensitization (Fig. 6). An
increased understanding of the regulatory factors that
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for appropriate regulation of the surface properties of
nanomaterials so that they can be used safely.
Conclusions
Cutaneous exposure to agglomerates of Dp and nSP30
induced an IgE-biased immune response in NC/Nga
mice and increased their sensitivity to anaphylaxis. Sur-
prisingly, these results were independent of the innate
biologic effects of nSP30; these results required both
simultaneous exposure to Dp and nSP30 and their ag-
glomeration. In particular, features of the mice with IgE-
biased immune response induced by cutaneous exposure
to agglomerates of allergen and nanoparticles resembled
those of humans with atopic allergies, who often have a
low IgG/IgE ratio; follow-up epidemiologic studies that
focus cutaneous compared with inhalational exposure to
nanomaterials might improve our understanding of the
onset of atopic allergy. In light of our findings, we sug-
gest that minimizing the interaction between nanoma-
terials and allergens may improve the safety of topically
applied products containing nanomaterials.
Methods
Silica nanoparticles
nSP30 and nSP30C (nSP30C is a surface modified nSP30
with carboxyl groups) silica nanoparticles (diameter,
30 mm) were purchased from Micromod Partikeltech-
nologie (Rostock/Warnemünde, Germany). Suspensions
of silica nanoparticles were stored at room temperature.
Immediately prior to use, the suspensions were sonicated
at 400 W for 5 min at 25 °C and then vortexed for 1 min.
Mice
Female NC/Nga slc mice were purchased from SLC
(Kyoto, Japan) and used at 6 wk of age. All animal exper-
iments were performed in accordance with the institutional
guidelines of Osaka University and National Institute of
Biomedical Innovation regarding the ethical treatment of
animals.
Preparation of the mixtures of Dp and nSP30s
To prepare the mixtures of nSP30s and Dp (Cosmo Bio
LSL, Tokyo, Japan), we first combined nSP30s (25 mg mL−1
in water) and concentrated PBS (1.1× to 4.6×; the concen-
tration of the PBS stock used depended on the concentra-
tion of nSP30s needed in the final sample, the diluent for
which was 1× PBS). We then added the stock solution of
Dp (2.78 mg protein mL−1 in PBS) to the solutions contain-
ing various concentrations of nSP30s. As soon as the
nSP30s and Dp solutions were combined, the mixtures
were vortexed for 1 min, allowed to incubate at room
temperature for 0.5 to 1.5 h, and vortexed again for 1 min
just prior to use.Physicochemical examination of silica nanoparticles
TEM (H-7650; Hitachi High-Technologies Corporation,
Tokyo, Japan) was used to assess the size and shape of
the silica nanoparticles. nSP30 and nSP30C nanoparti-
cles were diluted to 0.25 mg mL−1 in PBS or deionized
water, and the mean particle diameter and zeta potential
at 25 °C were measured by using a Zetasizer Nano ZS
(Malvern Instruments, Worcestershire, UK). Specifically,
the mean diameters and particle size distributions of the
nanoparticles were measured by means of a dynamic
light-scattering method, whereas zeta potentials were
measured by laser Doppler electrophoresis; both types
of measurements were performed by using capillary
cells (Malvern Instruments). The pH of each particle
suspension was measured by using an ISFET pH meter
(Shindengen, Tokyo, Japan).
Skin painting and assessment of allergic response
Using a hair-removal cream (Epilat; Kracie, Tokyo, Japan),
we removed the hair from the backs of all mice twice
during each experiment (on day 1 and on day 18–20).
Mice were treated either with Dp (1 mg mL−1 fin. conc)
alone or with silica nanoparticles (nSP30 or nSP30C,
12.5 mg mL−1 fin. conc.) in 120 μL PBS by painting the
ventral side of both ears and the depiliated dorsum
(20 μL per ear and 80 μL on the back) on alternate days
or every third day for 4 wk for a total of 13 applica-
tions. Additional mice were painted with Dp only on
one day followed by painting with nSP30 alone on the
next day; this alternating pattern was repeated for a
total of 13 applications of each solution over 4 wk. Re-
gardless of the dose schedule used, any sample remaining
from a previous application was removed by gently wiping
with a disposable wipe (Kim wipes, Crecia, Tokyo, Japan)
wetted with 70 % ethanol.
We used a dial thickness gauge (0.001-mm type; Ozaki
Manufacturing, Tokyo, Japan) to measure ear thickness
weekly. To evaluate the severity of the IgE-mediated al-
lergic response’ instead, we used a systemic anaphylaxis
model. Specifically, at 1 wk after the final skin painting,
each mouse was challenged with an intravenous injec-
tion of Dp (15 μg in 200 μL PBS). The severity of ana-
phylactic shock was assessed according to the change in
rectal temperature measured by using a digital therm-
ometer (KN-91; Natsume Seisakusho, Tokyo, Japan).
Histologic analysis
At 24 h after the final topical treatment, the ears of eu-
thanized mice were removed, placed in fixative solution
(4 % paraformaldehyde in PBS; Wako, Osaka, Japan),
embedded in paraffin, and sectioned. The tissue sections
were stained with hematoxylin and eosin or with tolui-
dine blue. Histopathological examination was performed
by the Applied Medical Research Laboratory (Osaka,
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(scab formation, acanthosis and inflammatory cell infil-
tration) were scored as follows: 0, none; 1, slight; 2, mild;
3, moderate; and 4, severe. In addition, we counted the
number of mast cells in 3 random high-power fields
(magnification, 400×).
Blood sampling
Using hematocrit capillary tubes (Terumo, Tokyo, Japan),
we obtained blood samples from the retro-orbital venous
plexus once each week during the study period. At 24 h
after the final skin painting, blood was collected by cardio-
centesis into heparin-treated syringes and centrifuged at
3000 × g at 4 °C; the resulting plasma was stored at −80 °C
until analysis.
Quantitation of total IgE concentration
The total IgE concentration in plasma was measured by
using an ELISA kit (BD Biosciences, San Diego, CA,
USA) according to the manufacturer’s instructions.
Detection of Dp-specific antibody
The levels of Dp-specific antibody in plasma were deter-
mined by ELISA. To detect IgG, IgG1, IgG2a, IgG2b and
IgG3, we coated ELISA plates (Maxisorp, type 96 F; Nunc
A/S, Roskilde, Denmark) with Dp in PBS (50 μg mL−1).
The coated plates were incubated with 2 % Block Ace
(Dainippon Sumitomo Pharmaceuticals, Osaka, Japan).
Plasma samples were diluted by 2 % Block Ace and these
dilutions were added to the Dp-coated plates. After incu-
bation with plasma, the coated plates were incubated with
a horseradish peroxidase–conjugated goat anti-mouse IgG,
IgG1, IgG2a, IgG2b or IgG3 solution (SouthernBiotech,
Birmingham, AL, USA) for two hours at room temperature.
After the incubation, the color reaction was developed with
tetramethyl benzidine (Moss, Inc.; Pasadena, MD, USA),
stopped with 2 N H2SO4, and measured at OD450–620 on a
microplate reader.
To detect Dp-specific IgE, we coated ELISA plates
(Maxisorp, type 96 F) with purified rat anti-mouse IgE
(2 μg mL−1; R35-72, BD Biosciences;), incubated them
with Block Ace, and added samples of diluted plasma as
described earlier. Treated plates were incubated with
biotin-conjugated Dp (5 μg mL−1) followed by horserad-
ish peroxidase–coupled streptavidin (Southern Biotech-
nology Associates). Color detection was performed as
described earlier.
Isolation of splenocytes
Spleens were removed aseptically and placed in RPMI
1640 (Wako) supplemented with 10 % fetal bovine
serum, 10 mL L−1 of a 100× nonessential amino acid
solution (Gibco, Invitrogen, Carlsbad, CA, USA), 50 μM
2-mercaptoethanol (Gibco), and 1 % antibiotic cocktail(10,000 U mL−1 penicillin, 10,000 μg mL−1 streptomycin,
25 μg mL−1 amphotericin B; Gibco). Single-cell suspen-
sions of splenocytes were treated with ammonium chlor-
ide to lyse the red blood cells; treated splenocytes then
were washed, counted, and suspended in RPMI 1640.
Cytokine assays
To determine antigen-specific cytokine (IFN-γ and IL-4)
responses, splenocytes (5 × 105 cells well−1) were stimu-
lated with Dp antigen (100 μg mL−1) in vitro. After 24 h
incubation at 37 °C (95 % room air, 5 % CO2), stimu-
lated splenocytes were washed, and the numbers of IFN-
γ- and IL-4-producing cells were determined by using
an ELISPOT assay kit (BD Biosciences) according to the
manufacturer’s instructions.
Measurement of amount of Dp adsorbed to silica
nanoparticles
Solutions of Dp (1 mg mL−1 fin. conc.) + each nSP im-
mediately after preparation in PBS or water for 30 min
at 25 °C were centrifuged (2 h, 40,000 × g, 4 °C). The
amount of Dp in the supernatant then was determined
spectrophotometrically (OD280; Nanodrop 2000, Thermo
Scientific, Kanagawa, Japan).
Statistical analysis
Statistical analyses were performed with Ekuseru-Toukei
2010 software (Social Survey Research Information Co.,
Ltd., Tokyo, Japan). All data are presented as means ±
SEMs. Significant differences between control groups
and experimental groups were determined by using the
Dunnett test; a P value less than 0.05 was considered
significant.
Methods for additional files are available in
(Additional file 5).
Additional files
Additional file 1: Effects of nSP30 nanoparticles alone on skin. (A)
Effect of topical treatment with nSP30 alone on ear thickness in NC/Nga
mice. (B, C) Histology of ear sections stained with (B) hematoxylin and
eosin (HE) or (C) toluidine blue (TB). Scale bar, 50 μm. (D) Scores for
several symptoms characteristics of AD as evaluated in HE-stained sections.
(E) Mast cell infiltration evaluated in TB-stained as the number of mast cells
per high-power (i.e., 400×) field. (F) Total IgE concentration at 24 h after
the final treatment. N. D., not detected (<30 ng mL-1). Data are given
as mean ± SEMs (n = 5).
Additional file 2: Dose-dependence of the effects of nSP30
nanoparticles on mite-allergen (Dp)-specific antibody responses. A-C,
Plasma levels of Dp-specific (A) IgE, (B) IgG, and (C) IgG subtypes in
plasma collected from NC/Nga mice after topical treatment with Dp
alone or with 1.4, 4.2, or 12.5 mg mL-1 nSP30 (as analyzed by ELISA). Data
are given as mean ± SEMs (n = 5). *P < 0.05. **P < 0.01 vs. Dp-alone group.
Additional file 3: Effects of nSP30 nanoparticles on effector
cytokines induced by mite allergen (Dp). Levels of Dp-specific effector
cytokines in the supernatants of NC/Nga mouse splenocytes stimulated
with 100 μg mL-1 Dp for 4 days (determined by use of cytokines
Hirai et al. Particle and Fibre Toxicology  (2015) 12:16 Page 13 of 14immunoassay or ELISA). Data are given as means ± SEMs (n = 5). *P <
0.05. **P < 0.01 vs. Dp-alone group.
Additional file 4: Effects of administration route of mite allergen
(Dp) + nSP30 mamoparticles on Dp-sepcific antibody response.
Levels of Dp-specific IgE and IgG in plasma collected from NC/Nga mice
after treatment with Dp alone or Dp + nSP30 by intradermal (foot-pad
injection), intranasal, or oral administration (as analyzed by ELISA). Data
are given as means ± SEMs (n = 3-6). **P < 0.01 vs. Dp-alone group.
Additional file 5: Additional methods.
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